Abstract
BACKGROUND This study aimed to evaluate the efficacy and safety of linagliptin (a novel dipeptidyl peptidase (DPP)-4 inhibitor) on glucose metabolism and β-cell function in Chinese patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus (T2DM). MATERIAL AND METHODS Newly-diagnosed and drug-naïve T2DM patients were enrolled. After 4-week lifestyle modulation and 2-week placebo run-in, 57 patients were randomized to double-blind treatment with linagliptin (n=34) or placebo (n=23). The primary endpoint was the change from baseline in glycosylated hemoglobin A1c (HbA1c) after 24 weeks. Fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2h-PPG), fasting insulin, proinsulin-to-insulin ratio, homeostasis model assessment of insulin resistance (HOMA-IR), and homeostasis model assessment of β-cell function (HOMA-β) were also evaluated. RESULTS Baseline characteristics were similar between the 2 groups. Compared with placebo, linagliptin therapy resulted in a significant decrease in HbA1C (-1.2±0.7% vs. -0.4±0.4%, P<0.001), FBG (-0.98±1.17 vs. -0.32±0.51 mmol/L, P=0.011, and 2h-PPG (-2.02±0.94 vs. -0.97±0.63 mmol/L, P<0.001). Significant differences were observed for the proinsulin/insulin ratio (P<0.001) and HOMA-...Continue Reading
References
Jul 1, 1985·Diabetologia·D R MatthewsR C Turner
Jun 8, 1999·JAMA : the Journal of the American Medical Association·R C TurnerR R Holman
Nov 28, 2007·Archives of Internal Medicine·Raquel VillegasXiao Ou Shu
Mar 21, 2008·Journal of Clinical Pharmacology·Goutam C MistryGary A Herman
Jul 22, 2008·Advances in Therapy·John Doupis, Aristidis Veves
Dec 23, 2008·Diabetes Research and Clinical Practice·Viswanathan MohanKeith D Kaufman
Apr 25, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·A B HauberH Falvey
Aug 5, 2009·Current Medical Research and Opinion·J RosenstockUNKNOWN CV181-011 Study Investigators
Mar 26, 2010·The New England Journal of Medicine·Wenying YangUNKNOWN China National Diabetes and Metabolic Disorders Study Group
Jan 6, 2011·Diabetes, Obesity & Metabolism·S Del PratoK A Dugi
Feb 10, 2011·The Tohoku Journal of Experimental Medicine·Susumu OgawaSadayoshi Ito
Dec 8, 2011·Diabetes, Obesity & Metabolism·R KawamoriK A Dugi
Jan 20, 2012·Kidney International·Adriana M HungMarie R Griffin
Jul 4, 2012·Lancet·Baptist GallwitzHans-Juergen Woerle
Aug 11, 2012·Clinical Medicine Insights. Endocrinology and Diabetes·Baptist Gallwitz
Sep 15, 2012·Diabetes, Obesity & Metabolism·A H BarnettH-J Woerle
Apr 17, 2013·Diabetes Care·Elizabeth R SeaquistRobert Vigersky
May 16, 2013·Current Medical Research and Opinion·Zhengpei ZengHans-Juergen Woerle
Jul 11, 2013·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
Aug 27, 2013·European Journal of Internal Medicine·Pietro Amedeo Modesti
May 16, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·M BajajH-J Woerle
Mar 11, 2015·Journal of Diabetes·Weiqing WangGuang Ning
Citations
Dec 6, 2016·Diabetes Technology & Therapeutics·Xiaoling CaiLinong Ji
Sep 19, 2017·Journal of Diabetes Investigation·Ronald Cw MaStuart A Ross
Aug 19, 2017·Advances in Therapy·Guang NingJuliana C N Chan
Mar 26, 2019·Diabetes/metabolism Research and Reviews·Weiping JiaUNKNOWN Chinese Diabetes Society
Mar 25, 2020·Diabetology International·Nobuya InagakiMasaomi Nangaku
Jan 11, 2020·Endocrinology, Diabetes & Metabolism·Sanaz KamaliniaSheldon W Tobe
May 2, 2017·CMAJ Open·Subodh VermaJan O Friedrich
Nov 17, 2020·BMC Medicine·Chu LinLinong Ji